Fibrodysplasia Ossificans Progressiva Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Conditions: Fibrodysplasia Ossificans Progressiva Sponsors: Ipsen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2023 Category: Research Source Type: clinical trials
A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)
Conditions: Fibrodysplasia Ossificans Progressiva (FOP) Interventions: Other: Non-Interventional Sponsors: Regeneron Pharmaceuticals Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
The Examination of Safety and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Condition: Fibrodysplasia Ossificans Progressiva Interventions: Drug: Garetosmab; Drug: Placebo Sponsor: Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2022 Category: Research Source Type: clinical trials
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Condition: Fibrodysplasia Ossificans Progressiva (FOP) Interventions: Drug: INCB000928; Drug: placebo Sponsor: Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2021 Category: Research Source Type: clinical trials
